ArticleNature chemistry2022
A modular XNAzyme cleaves long, structured RNAs under physiological conditions and enables allele-specific gene silencing.
Article in Nature chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Chemical Modification Strategies for Therapeutic Oligonucleotides: Mechanism Compatibility, Design Trade-Offs, and Translational Barriers.Molecules (Basel, Switzerland) · 2026Review
- The 10-23 DNAzyme in Biosensing and Diagnostics: Applications, Challenges, and Future Directions.Angewandte Chemie (International ed. in English) · 2026Review
- De novo-designed ribozyme-controlled riboregulator for cell-free diagnostics.Nature communications · 2026Article
- Advances in DNAzyme Selection, Molecular Engineering and Biomedical Applications.International journal of molecular sciences · 2026Review
- Chemically modified DNA aptamers and DNAzymes for expanded functional capabilities.Chemical science · 2026Review
- A modified X10-23 DNAzyme that can better access large, structured RNA targets.Nucleic acids research · 2026Article
- Functions and applications of enzymes in nucleic acid nanotechnology.Journal of nanobiotechnology · 2025Review
- Functional Analysis of Histidine-Dependent Self-Cleaving RNAs Obtained by In Vitro Selection.Chembiochem : a European journal of chemical biology · 2025Article
- Enzymatic Synthesis of Mixed XNA Polymers Containing 2'Fluoro and 2'Azide Modifications.ACS omega · 2025Article
- The coming of age of DNA-based catalysts for therapeutic applications.Clinical and translational medicine · 2025Article
- A solid-phase enzymatic synthesis platform for the facile production of 2'-fluoroarabinonucleic acid (FANA) and chimeric XNA oligonucleotides using an evolved XNA polymerase.Nucleic acids research · 2025Article
- Chemical evolution of ASO-like DNAzymes for effective and extended gene silencing in cells.Nucleic acids research · 2025Article
- Opening new frontiers with catalytic nucleic acids in miRNA inhibition.Frontiers in pharmacology · 2025Review
- L-Histidine Modulates the Catalytic Activity and Conformational Changes of the HD3 Deoxyribozyme.Genes · 2024Article
- TNA-Mediated Antisense Strategy to Knockdown Akt Genes for Triple-Negative Breast Cancer Therapy.Small methods · 2024Article
- Making target sites in large structured RNAs accessible to RNA-cleaving DNAzymes through hybridization with synthetic DNA oligonucleotides.Nucleic acids research · 2024Article
- Template-independent synthesis and 3'-end labelling of 2'-modified oligonucleotides with terminal deoxynucleotidyl transferases.Nucleic acids research · 2024Article
- Advancing the enzymatic toolkit for 2'-fluoro arabino nucleic acid (FANA) manipulation: phosphorylation, ligation, replication, and templating RNA transcription.Chemical science · 2024Article
- Controlled enzymatic synthesis of oligonucleotides.Communications chemistry · 2024Review
- DNAzyme-Catalyzed Site-Specific N-Acylation of DNA Oligonucleotide Nucleobases.Angewandte Chemie (International ed. in English) · 2024Article
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
Nucleic-acid catalysts (ribozymes, DNA- and XNAzymes) cleave target (m)RNAs with high specificity but have shown limited efficacy in clinical applications. Here we report on the in vitro evolution and engineering of a highly specific modular RNA endonuclease XNAzyme, FR6_1, composed of 2'-deoxy-2'-fluoro-β-D-arabino nucleic acid (FANA). FR6_1 overcomes the activity limitations of previous DNA- and XNAzymes and can be retargeted to cleave highly structured full-length (>5 kb) BRAF and KRAS mRNAs at physiological Mg
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.